Clinical Trials Directory

Trials / Completed

CompletedNCT07129707

Nasal High-flow Oxygen Therapy During Acute Exercise in Fibrotic Interstitial Lung Disease

Does Nasal High-flow Oxygen Potentiate the Effects of Rehabilitative Exercise Training in Chronic Fibrotic Interstitial Lung Disease?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Dieulefit Santé Centre de Réadaptation · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Hallmarks of fibrotic interstitial lung disease (f-ILD) include severe hypoxemia, dyspnea and exercise limitation. Although ambulatory oxygen (O2) therapy is widely prescribed, standard low-flow O2 systems (nasal prongs) fail to meet patients' inspiratory demand on exertion resulting in incomplete correction of hypoxemia and limited symptomatic relief. Nasal high-flow O2 therapy (NHFO2) delivers heated, humidified, and O2-enriched air at high flow rates. It has recently emerged as a promising alternative to overcome the pre-specified limitations: NHFO2 is more effective in correcting hypoxemia and reducing dyspnea vs standard O2 therapy and consistently improved exercise capacity in f-ILD. In fact, NHF per se may exert independent physiological benefits such as washout of the anatomical dead space and reduced work of breathing. However, the respective effect of respiratory support and improved oxygenation on dyspnea and exercise tolerance remain unexplored in f-ILD. To address this gap in knowledge, this prospective, randomized-controlled trial aimed to disentangle the i) independent and ii) combined effects of respiratory support and supplemental O2 on dyspnea and exercise tolerance in patients with f-ILD.

Conditions

Interventions

TypeNameDescription
OTHERExercise testingEach participant performs a constant work-rate exercise test (70% peak work rate) under the 4 experimental conditions (referred as arms).

Timeline

Start date
2023-12-01
Primary completion
2025-01-31
Completion
2025-01-31
First posted
2025-08-19
Last updated
2025-08-19

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07129707. Inclusion in this directory is not an endorsement.